Nachrichten zur ImmunityBio Inc. Aktie

ImmunityBio Inc. (IBRX): H.C. Wainwright sieht Potenzial für ANKTIVA bei therapieresistenten nicht-muskelinvasiven Blasenkrebserkrankungen

ImmunityBio Inc. (IBRX) (i.) ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von Next-Generation-Therapien und Impfstoffen konzentriert, die das natürliche…

ImmunityBio shares surge following progress in FDA discussions By Investing.com

ImmunityBio shares surge following progress in FDA discussions…

ImmunityBios Cash Burn And Dilution Dampen Anktivas Potential

…

Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move

Biotech billionaire Patrick Soon-Shiong was accused in a shareholder lawsuit of misleading ImmunityBio Inc. investors about the prospects of the…

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ImmunityBios Anktiva: Promising, But Organizational Complexity Keeps Me Cautious

…

ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of -17.65% and 58.54%, respectively, for the quarter ended June 2024. Do the…

ImmunityBio spikes after commercial update on lead drug Anktiva

…

ImmunityBio shares target raised by Piper Sandler on potential approval By Investing.com

ImmunityBio shares target raised by Piper Sandler on potential approval…

ImmunityBio mit positivem Momentum

Die Bekämpfung von Krebs ist zentrales Thema für viele Biotech-Unternehmen. ImmunityBio, hinter der der bekannte Investor, Forscher und Erfinder Patrick…

dpa-AFX ProFeed